Unveiling the Global Landscape of Rheumatoid Arthritis Clinical Trials, with Judith Ng-Cashin, MD [Video]

In an interview with HCPLive, Judith Ng-Cashin, MD, chief medical officer at Novotech, discusses the recent Rheumatoid Arthritis – Global Clinical Trial Landscape report.

What might surprise some people, Ng-Cashin explains, is the amount of clinical trial activity focused on rheumatoid arthritis (RA) treatment occurring outside of the US, particularly in the Asia Pacific (APAC) region. There is a significant amount of activity in countries like China and South Korea, especially in early phases. This reflects the robust biotech and pharma activity surrounding biologics in general. This momentum is due in part to advancements in science, particularly in immunomodulators, encompassing both novel targets and pathways as well as biosimilars.

Development in this space is expected to continue, driven by innovation around immunomodulating targets within interleukin, tumor necrosis factor (TNF), Janus kinase (JAK) pathways, as well as biosimilars. Despite the initial challenges in the biosimilar market meeting industry hopes for increased competition, price competition, affordability, and accessibility in developing markets, there is optimism that biosimilars will eventually deliver on these expectations.

https://www.hcplive.com/view/unveiling-the-global-landscape-of-rheumatoid-arthritis-clinical-trials-with-judith-ng-cashin-md